Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
VANCOUVER, BC, Oct. 20, 2021 /CNW/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”), a leader in psychedelics-focused mental healthcare, is pleased to have finalized the study design and protocol for a Phase 1 clinical trial on…